Gupta Sonia, Rakhra Amandeep, Thallapally Vinay, Nahas Joseph
Department of Internal Medicine, Creighton University, Omaha, Nebraska, USA.
Department of Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Intractable Rare Dis Res. 2021 May;10(2):122-125. doi: 10.5582/irdr.2020.03144.
Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy.
免疫抑制是抗3-羟基-3-甲基戊二酰辅酶A还原酶（抗HMGCR）肌病的基石疗法。典型的免疫抑制剂，如皮质类固醇、甲氨蝶呤和硫唑嘌呤，已与去除致病因素联合使用，但利妥昔单抗在这类肌病中的应用更为有限。本文报告了1例患者，在标准免疫抑制剂治疗失败后，对利妥昔单抗（RTX）反应良好。该病例说明了进一步研究以评估RTX在抗HMGCR肌病中作用的重要性。
